|
WO2016102641A1
|
|
Methods and pharmaceutical compositions for the treatment of acute exacerbations of chronic obstructive pulmonary disease
|
|
WO2016102536A1
|
|
Methods and pharmaceutical compositions for the treatment of bacterial superinfections post-influenza
|
|
WO2016097260A1
|
|
Methods for predicting or diagnosing autism spectrum disorders (asd)
|
|
WO2016097175A1
|
|
New method for treating pancreatic cancer
|
|
WO2016096914A1
|
|
Methods for testing the presence of protective antigen-induced memory cd8+ t cells
|
|
WO2016092045A1
|
|
Methods and kits for predicting medically refractory acute severe colitis
|
|
WO2016092041A1
|
|
Methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (hiv-1) infections
|
|
WO2016083466A1
|
|
Novel tumor suppressor gene and uses thereof for the treatment and diagnosis of cancer
|
|
WO2016079067A1
|
|
Compounds targeting the bfl-1 anti-apoptotic protein and uses thereof for the treatment of cancer
|
|
WO2016066671A1
|
|
Method for treating resistant cancers using progastrin inhibitors
|
|
WO2016066608A1
|
|
Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging
|
|
WO2016066618A2
|
|
Compositions and methods for antigen-specific tolerance
|
|
WO2016059220A1
|
|
Tcr-activating agents for use in the treatment of t-all
|
|
WO2016046321A1
|
|
Method for treating cancer and infectious diseases
|
|
WO2016042137A1
|
|
Method for diagnosing myeloproliferative chronic myelomonocytic leukemia or unclassified myeloproliferative myelodysplastic neoplasm
|
|
WO2016034742A1
|
|
Methods of diagnosing and treating cancer
|
|
WO2016008937A1
|
|
Methods for the intercellular transfer of isolated mitochondria in recipient cells
|
|
WO2016005432A1
|
|
A new biomarker of chronic allograft nephropathy and of renal transplant rejection
|
|
WO2016005422A1
|
|
Methods and compositions for treating neuropathic pain
|
|
WO2016005424A1
|
|
Methods for assessing mineralocorticoid receptor activation in adipose tissue of a subject and treating metabolic syndrome
|
